{"id":"NCT01614457","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-06-08","resultsPosted":"2015-02-12","lastUpdate":"2015-02-12"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ivacaftor","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.","primaryOutcome":{"measure":"Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Ivacaftor","deltaMin":2.5724,"sd":1.1532},{"arm":"Placebo","deltaMin":0.4611,"sd":1.1313}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1979"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":31,"countries":["United States","United Kingdom"]},"refs":{"pmids":["26070913"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":34},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Headache","Sputum increased","Diarrhoea"]}}